Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 10.07M P/E - EPS this Y 71.00% Ern Qtrly Grth -
Income -17.23M Forward P/E -0.48 EPS next Y 54.80% 50D Avg Chg -8.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book 0.66 EPS next 5Y - 52W High Chg -51.00%
Recommedations 2.00 Quick Ratio 0.35 Shares Outstanding 4.89M 52W Low Chg 41.00%
Insider Own 6.16% ROA -91.42% Shares Float 4.59M Beta 1.13
Inst Own 0.50% ROE -362.29% Shares Shorted/Prior 415.26K/153.42K Price 0.86
Gross Margin - Profit Margin - Avg. Volume 33,508 Target Price 3.00
Oper. Margin - Earnings Date - Volume 26,747 Change -5.44%
About Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Virpax Pharmaceuticals, Inc. News
04:05 PM Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative
11/18/24 Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering
11/15/24 Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
11/13/24 Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
11/05/24 Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer
08/13/24 Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments
08/08/24 Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15
07/24/24 Virpax Regains Compliance with Nasdaq Minimum Bid Price
07/10/24 Pain Management-Focused Penny Stock Virpax Pharmaceuticals Surges Over 100% On Wednesday-Here's Why?
07/10/24 Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™
07/08/24 Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding
05/29/24 Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
05/15/24 Virpax Announces Pricing of $2.25 Million Public Offering
05/13/24 Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments
04/30/24 Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
03/26/24 Virpax Pharmaceuticals Reports 2023 Year-End Results
02/27/24 Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price
02/27/24 Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
02/07/24 Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
12/29/23 Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting
VRPX Chatroom

User Image stockWare Posted - 57 minutes from now

$VRPX swinging this

User Image The_Hungry_Wolf Posted - 50 minutes from now

$SKK who was that person who mentioned $SKK on $VRPX page? I just wanted to thank you and say I love you to you

User Image First_Class_Seaman Posted - 44 minutes from now

$ABVE getting tough but will pay nice $CTV might be another leg up tmr $VRPX got a starter. Watching close for tmr

User Image SBW_Trades Posted - 44 minutes from now

$BENF $VRPX $SKK📈🔥

User Image AlertsAndNews Posted - 42 minutes from now

Gappers in after hours trading $VRPX $MTEM $EYEN $MMA $SKK Ill try and update later this evening.

User Image GSP Posted - 41 minutes from now

The last 5 stocks in my watch list video for November 22nd: $LUNR $SMCI $FSLY $TGT $VRPX Watch the video here: https://greatstockpix.com/november-22nd-day-trading-watch-list/ .

User Image walfofwallstreet Posted - 29 minutes from now

My holding into tomorrow part 1 $SKK $EYEN $MTEM $WORX $VRPX All my followers are making banks 🏦

User Image JayZeeBee7 Posted - 23 minutes from now

$AZI The run is imminent, just a matter of time before this jewel explodes. Shorts still didn’t cover their 1.2M shares and they are in deep. Current rate is 104. 2.5M free float! 3 13Gs filings. WW. $VRPX nice run! Awesome news. Keeping an eye on. $MTEM Consolidating right now.

User Image Rasto2020 Posted - 18 minutes from now

$VRPX too many eyes on it for tomorrow. Some will wait to get in lower, but it might not happen. Either way, I wish everyone all the best

User Image mh191 Posted - 12 minutes from now

$VRPX won't buy tonight, but definitely have eyes on it tomorrow pm

User Image Eienek_ Posted - 6 minutes from now

$VRPX fyi the collaboration mentioned in the recent article today is the same as the one announced on August 31, 2020. In 2020, Virpax Pharmaceuticals entered into a cooperative research and development agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to develop NES100, an intranasal enkephalin formulation for managing acute and chronic non-cancer pain. https://virpaxpharma.com/2020/08/31/virpax-enters-nih-collaboration-to-develop-nes100-acute-chronic-non-cancer-pain/ The recent announcement indicates that this existing collaboration has been extended to continue the development of NES100.

User Image walfofwallstreet Posted - 6 minutes from now

$SKK $EYEN $MTEM $VRPX $WORK 🔥🔥🔥🔥 👀 All my followers are making banks 💰🏦

User Image Tamim_Walizada Posted - 2 minutes from now

$VRPX

User Image 1FARMMAN Posted - 18 seconds from now

$EYEN They loaded more shares! 2024-11-14 13G/A ARMISTICE CAPITAL, LLC 4,378,000 8,600,000 This is going to breakout GL BULLS WN $VRPX $MTEM $TNXP $MSTZ

User Image YouVSYou Posted - 5 minutes ago

$VRPX bull pennant looks like $worx this morning

User Image Milkcrumb Posted - 19 minutes ago

$VRPX 0 short shares left, and a few warrants at 1.35 might as well go snag those

User Image 1FARMMAN Posted - 36 minutes ago

$EYEN This is going to breakout GL BULLS WN $VRPX $MTEM $TNXP $MSTZ

User Image drasa855 Posted - 38 minutes ago

$REPL $EYEN $VRPX $SKK on watch for morning movers! like the after hours action!

User Image MarketMomentums Posted - 40 minutes ago

$ABVE Bulls are holding for the big move here. ABVE -->7.3m Cash on hand, low float, no risk of dilution check🚀 $EYEN Huge run $VRPX Loaded heavy in the .80s banked!

User Image OpStockMarketGarden Posted - 40 minutes ago

$VRPX Ok.

User Image TheGreatestLover Posted - 46 minutes ago

$VRPX https://www.businesswire.com/news/home/20241121242163/en/

User Image Uncagedpages Posted - 51 minutes ago

$CRKN $DJT $MTEM $VRPX $WORX Be sure to remember the insiders aren’t through selling. Dilution is still on the table, also. “…One-quarter of Juhan's restricted stock units will become eligible for sale on Dec. 25, 2024, and the remaining shares will vest in quarterly installments through March 2027. Scott Glabe, Trump Media's general counsel and secretary, on Friday sold 15,917 shares for $32.19 per share, or a total of $512,368, an SEC filing shows. Glabe still holds 336,576 restricted stock units in Trump Media which will vest according to the same schedule as Juhan's RSUs. Eric Swider, director, sold 136,183 shares of DJT on Friday at $28.23 per share, or a total of $3.84 million in stock, according to his Form 4 filing. Swider disposed of all of his shares, but his company, Renatus Advisors, still owns 18,043 shares of Trump Media…” https://www.benzinga.com/general/social-media/24/11/41993328/trump-media-insiders-sell-more-than-16-million-in-djt-stock

User Image Craneton Posted - 53 minutes ago

$CLSK $HOLO $VRPX $WULF Wrong board.

User Image cjstocksup Posted - 58 minutes ago

$VRPX Push shorts up hard over $1.30 and we get $1.50 soon after IMO.

User Image DaBullRunner Posted - 59 minutes ago

$CRKN kinda reminds me of when DWAC now know as $DJT went parabolic The TRUMP theme can take this ticker to LIFE CHANGING levels $MTEM $VRPX $WORX let’s get it

User Image nader_1 Posted - 1 hour ago

$VRPX I am in at $0.75, i will sell some tomorrow at 1.50 leave the rest after multiple halts - $2.50

User Image TheGov65 Posted - 1 hour ago

$VRPX You mean this company makes Tylenol? Ibuprofen? 🤣 Stick with Oxycodone, Hydrocodone and 5 other types my doctor prescribed for me monthly!

User Image walfofwallstreet Posted - 1 hour ago

My top list for tomorrow $SKK $EYEN $MTEM $WORK $VRPX Let’s make more money 💵💰 all my followers are making banks 🏦 You all are gonna to be rich 🤑

User Image Weatherman118 Posted - 1 hour ago

$VRPX what a banger to end the day! +50% gains for the members in the community! 🔥💰🎯

User Image The_Hungry_Wolf Posted - 1 hour ago

$VRPX last time we shot up like this we went to 1.67 Today we're 100% up 😍 Get in now $AZI $PHUN $HUSA

Analyst Ratings
Maxim Group Buy Jul 19, 24
Maxim Group Hold May 22, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Sendrow Jerrold Director Director May 24 Buy 1.29 4,500 5,805 9,006 05/26/22
Mack Anthony P. Chief Executive Offi.. Chief Executive Officer May 18 Buy 1.34 75,750 101,505 252,562 05/20/22
Floyd Eric Director Director May 18 Buy 1.3635 4,479 6,107 8,018 05/20/22